Core Points - Bakkt Holdings, Inc. has filed post-effective amendments to its registration statements on Form S-3 with the SEC, including a shelf registration statement originally filed in June 2025 [1] - The amendments were prompted by the company's transition from an umbrella partnership-C corporation structure to a single class of common stock, with no additional securities being registered [1] - The SEC has not yet declared the registration statements effective, and the press release does not constitute an offer to sell or solicit an offer to buy any securities [2] Company Overview - Bakkt, founded in 2018, is focused on building next-generation financial infrastructure, providing solutions for institutional participation in the digital asset economy, including Bitcoin, tokenization, stablecoin payments, and AI-driven finance [3] - The company emphasizes scale, security, and regulatory compliance, positioning itself at the center of a transformation in financial transactions and market operations [3] - Bakkt is headquartered in New York, NY [4]

Acting Chairman Pham Continues To Carry Out President Trump’s Mandate To Make America the Crypto Capital of the WorldNEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Today, Gemini Space Station, Inc. (Gemini) (NASDAQ:GEMI) announced that Gemini Titan, LLC (Titan), an affiliate, received a Designated Contract Market (DCM) license from the Commodity Futures Trading Commission (CFTC), which will allow Gemini to begin offering prediction markets to U.S. customers. Gemini first applied for a DCM license on March 10, ...

Core Insights - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, totaling 39,575 shares in stock options and 26,525 RSUs [1][2] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - The lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for adults with acromegaly who have not responded adequately to surgery [4] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors, with a pipeline that includes over 10 disclosed programs targeting various endocrine conditions [4]

Core Insights - Serina Therapeutics has submitted a complete response to the FDA regarding the clinical hold on its lead drug candidate SER-252 for advanced Parkinson's disease, addressing concerns related to a formulation excipient [1][2][3] - The company is targeting the first patient in for the registrational Phase 1b study in Q1 2026, contingent on FDA feedback and resolution of the clinical hold [1][3] Company Overview - Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug candidates for neurological diseases, utilizing its proprietary POZ Platform for drug optimization [4] - The POZ technology is based on a synthetic polymer that enhances drug delivery and stability, potentially improving the efficacy and safety profiles of various therapeutic modalities [5] Drug Development Details - SER-252 is an investigational apomorphine therapy designed to provide continuous dopaminergic stimulation, which may reduce levodopa-related motor complications in Parkinson's disease [8] - The complete response to the FDA includes a detailed data package supporting the use of trehalose as a subcutaneous excipient and a revised protocol for the single ascending dose phase of the trial [7]

London, United Kingdom, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Daedalus Special Acquisition Corp. (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Co-Chief Executive Officers Husnu Akin Babayigit and Orkun Kilic, today announced the closing of its upsized pricing of its initial public offering of 25,000,000 units, which includes 2,500,000 units issued pursuant to the partial exercise by the underwriters of their over-allotment option, a ...

Hong Kong, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Abits Group Inc. (NASDAQ: ABTS), a new generation digital center with inhouse bitcoin mining operations, today announced its unaudited results for the third quarter ended September 30, 2025 which reflect continued solid progress at both its sites in Tennessee. Highlights of the Quarter ●Total revenue reached $1.61 million in Duff, Tennessee, representing a 27.5% increase compared to the same period last year. Profit of this self-owned mining operation was $0.76 ...

CALGARY, Alberta, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Canoe EIT Income Fund (“Canoe” or the “Fund”)(TSX - EIT.UN) today announced that units accepted for the 2025 voluntary cash redemption will be redeemed at a price of $15.36 per unit (rounded) in Canadian dollars. This price is equal to 95% of the average net asset value per unit based on the three business days preceding the redemption date of December 5, 2025, less direct costs. Payment of the redemption proceeds will be made on or before December 30, 202 ...

BETHESDA, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, will report fourth quarter 2025 financial results on Wednesday, February 18, 2026, after the market close. The Company will hold a conference call to discuss its fourth quarter 2025 results and business outlook on Thursday, February 19, 2026, at 10:00 a.m. ET. Conference call access information is as follows: Conference Call: USA/Canada Toll ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion dollar pillar of cancer care, hampered by widespread resistanceThe study achieved its objective, as the new Q6W extended dosing interval produced encouraging anti-tumor efficacy and immunological data in prior immune-oncology refractory or relapsed patients including anti-PD- (L)1 checkpoint inhib ...

ALEXANDRIA, Va., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Serve Robotics Inc. (Nasdaq: SERV), a leading autonomous sidewalk delivery company, and the City of Alexandria today announced the launch of Serve’s on-demand robotic delivery service in Alexandria, Virginia. In partnership with Uber Eats, the delivery-platform of Uber Technologies (NYSE: UBER), residents and businesses in North East Alexandria, Del Rey, Potomac West, Old Town North, and nearby neighborhoods will now have the option to receive their orders ...